LobbyingImmunitybio lobbying by quarter
Immunitybio IBRX's latest lobbying report covers Q2 2026, at under $5,000. The four quarters Q4 2025–Q3 2026 total $120K. Its first report covers Q4 2025; the issues it reports most are Health Issues.
ImmunitybioIBRX
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $120K
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2025 | $60K | 1 |
| Q1 2026 | $60K | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$60K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Food & Drug Administration (FDA)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Continental Strategy | $120K | 3 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| TIMOTHY COSTA | Chief of Staff to Dan Meuser | Q4 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/19for Q2 | Continental Strategy | Under $5,000 |
| 04/18for Q1 | Continental Strategy | $60K |
| 01/19for Q4 2025 | Continental Strategy | $60K |
| 25/10/22for Q4 2025 | Continental Strategy | Under $5,000 |